openPR Logo
Press release

Orphan Diseases Market Is Expected To Grow At Stupendous Average CAGR Of 24.9% by 2022

12-18-2017 06:03 PM CET | Health & Medicine

Press release from: Market Research Future

Orphan Diseases

Orphan Diseases

Global Orphan Diseases Market also known as rare disease is growing rapidly. Furtherance in innovation, new creating methods can likewise bring about the development of the Orphan Diseases advertise. A noteworthy lump of this expansion popular of Orphan Diseases Market can be credited to the expanding maturing populace on the planet as it is substantially more likely for matured individuals to require

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2547 .

It affects a very small percentage of the global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe.

Global orphan diseases market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022. . However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the global orphan diseases market.

Involved Companies for Global Orphan diseases Market: AbbVie Inc. (US), Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US).

Regional Analysis of Global Orphan diseases Market:

Considering the worldwide situation of this market, North American region is believed to be the biggest market of the worldwide orphan diseases market. Additionally the European market is likewise developing and is the second biggest market for global orphan diseases market. Then again, Asia-Pacific's vagrant sickness showcase is required to develop at a noteworthy rate amid the gauge period. Rest of the World is likely to have a limited but steady growth with respect to this market.   

Browse Report @ https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547 .

Market Segmentation:

On the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others.

Treatment type it segmented into gene therapy, cell therapy, drug therapy and others.

End user the market is segmented into hospital and clinics, research laboratory and others.

Table of Content:

1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
6 Global Orphan Diseases Market, By Disease Type (USD Million)
7 Global Chronic Disease Management Market, By Treatment Type (USD Million)
8 Global Chronic Disease Management Market, By End User (USD Million)
9 Global Orphan Disease Market, By Region (USD Million)
10 Company Landscape
11 Company Profiles

Get Discount for Report @ https://www.marketresearchfuture.com/check-discount/2547 .

Intended Audience:

Hospitals and clinics

Orphan diseases drug manufacturers and suppliers

Government and independent regulatory authorities

Research and development (R&D) companies

Market research and consulting service providers

Medical research laboratories

Potential investors

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst.

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Diseases Market Is Expected To Grow At Stupendous Average CAGR Of 24.9% by 2022 here

News-ID: 866118 • Views:

More Releases from Market Research Future

Denim Market Size By 2035 with 5.25 USD Billion in 2025 to 132.4 USD Billion, Due To Due to increasing popularity of Denim jeans, Denim jackets, and other denim apparel.
Denim Market Size By 2035 with 5.25 USD Billion in 2025 to 132.4 USD Billion, Du …
Denim Market Size Grow at a 75.25 USD Billion in 2025 to 132.4 USD Billion by 2035, CAGR of 5.81% By 2025 - 2035 Global Denim Market is entering a new phase of transformation as consumer demand, fashion cycles, and sustainable innovation continue to reshape the industry. Denim, once considered a classic wardrobe staple, has evolved into a versatile, fashion-driven category supported by innovations in fabric technology, eco-friendly production, and shifting
Humanoid Robots Market Size to Reach USD 13.8 Billion by 2032, Growing at 50.2% CAGR from 2024
Humanoid Robots Market Size to Reach USD 13.8 Billion by 2032, Growing at 50.2% …
The global Humanoid Robots Market is projected to reach USD 13.8 Billion by 2032, growing at a robust CAGR of 50.2% during the forecast period from 2024 to 2032. Driven by advancements in artificial intelligence, machine learning, and machine vision, humanoid robots-designed with human-like characteristics-are witnessing widespread adoption across healthcare, education, space exploration, and service industries. These robots are enhancing operational efficiency, performing complex tasks, and improving customer engagement across multiple
Vertical Farming Market Expansion: USD 9.023 Billion in 2025 Growing to USD 58.83 Billion by 2035
Vertical Farming Market Expansion: USD 9.023 Billion in 2025 Growing to USD 58.8 …
The Vertical Farming Market was estimated at USD 7.48 Billion in 2024 and is projected to grow from USD 9.023 Billion in 2025 to USD 58.83 Billion by 2035, exhibiting a robust CAGR of 20.62% during the forecast period from 2025 to 2035. Driven by increasing demand for sustainable agriculture, urbanization, and technological advancements in controlled-environment farming, vertical farming solutions are seeing widespread adoption across commercial, industrial, and urban agriculture sectors. Key
Robotics Market Trends and Forecast: USD 74,120.70 Million in 2024 Expected to Hit USD 476,019.67 Million by 2035
Robotics Market Trends and Forecast: USD 74,120.70 Million in 2024 Expected to H …
The Robotics Market was valued at USD 74,120.70 Million in 2024 and is projected to reach USD 476,019.67 Million by 2035, growing at a robust CAGR of 18.4% during the forecast period from 2024 to 2035. Driven by advancements in medical robots, growing industrial robotics adoption, and the development of AI technologies, robotics solutions are witnessing widespread adoption across healthcare, manufacturing, logistics, and service sectors. Despite challenges like high initial costs

All 5 Releases


More Releases for Orphan

Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031. Get Free Access to
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry …
Market Overview: According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028 Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the